SCHEMBL8229079

SCHEMBL8229079

CC(C)(C)OC(=O)Nc1ccc(C2=CC(=O)CC2)cc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 6/20 0.42
CYP17A1 P05093 1/20 0.40
ABL1 P00519 3/20 0.38
PIK3CD O00329 1/20 0.38
EGFR P00533 1/20 0.38
KDR P35968 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CG P48736 1/20 0.38
BACE1 P56817 1/20 0.38
PRKDC P78527 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
MAP4K4 O95819 1/20 0.37
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
ABCB1 P08183 2/20 0.36
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
PTK6 Q13882 1/20 0.36
ABCC1 P33527 2/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8223596 0.82 ABCB1 (0.42) ABCB1ABCC1
SCHEMBL4579945 0.81 ABCB1 (0.38) AAK1HDAC1HDAC2ABCB1ABCC1
SCHEMBL30118380 0.80 HDAC2 (0.53) HDAC1HDAC2
SCHEMBL3786645 0.78 AAK1 (0.53) AAK1CYP17A1MAP4K4HDAC1HDAC2
SCHEMBL3786741 0.78 AAK1 (0.45) AAK1CYP17A1MAP4K4HDAC1HDAC2
SCHEMBL5868949 0.78 AAK1 (0.50) AAK1CYP17A1ABL1PIK3CDEGFR
SCHEMBL24233399 0.77 AAK1 (0.52) AAK1CYP17A1MAP4K4HDAC1HDAC2
SCHEMBL5868802 0.77 ABCB1 (0.54) AAK1CYP17A1MAP4K4HDAC1HDAC2
SCHEMBL5869075 0.77 AAK1 (0.52) AAK1CYP17A1MAP4K4ABCB1ABCC1
SCHEMBL1753916 0.77 ABCB1 (0.54) AAK1CYP17A1MAP4K4HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 AAK1 2271/4885CYP17A1 2210/4885ABL1 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.